References

Sustained Virologic Response to Direct‐Acting Antiviral Therapy in Patients With Chronic Hepatitis C and Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis

10.1016/j.jhep.2019.04.017 · 2019 · External reference

Hepatocellular Carcinoma Decreases the Chance of Successful Hepatitis C Virus Therapy With Direct‐Acting Antivirals

10.1016/j.jhep.2017.01.020 · 2017 · External reference

Effectiveness of Hepatitis C Antiviral Treatment in a USA Cohort of Veteran Patients With Hepatocellular Carcinoma

10.1016/j.jhep.2017.02.027 · 2017 · External reference

Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication

10.1093/cid/ciz1160 · 2020 · External reference

Clinical Practice Guidelines Panel: Chair: EASL Governing Board representative: Panel members chairs. EASL Recommendations on Treatment of Hepatitis C: Final Update of the Series

10.1016/j.jhep.2020.08.018 · 2020 · External reference

10.1093/cid/ciad319

10.1093/cid/ciad319 · External reference

Taiwan Consensus Statement on the Management of Hepatitis C: Part (II) Special Populations

10.1016/j.jfma.2020.04.002 · 2020 · External reference

EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma

10.1016/j.jhep.2018.03.019 · 2018 · External reference

AASLD Practice Guidance on Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma

10.1097/hep.0000000000000466 · 2023 · External reference

Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

10.1056/nejmoa1915745 · 2020 · External reference

EASL Clinical Practice Guidelines on the Management of Hepatocellular Carcinoma

10.1016/j.jhep.2024.08.028 · 2025 · External reference

Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence‐Based Approach‐The ALBI Grade

10.1200/jco.2014.57.9151 · 2015 · External reference

Validation and Potential of Albumin‐Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function

10.1159/000479984 · 2017 · External reference

Hepatocellular Carcinoma Risk Following Direct‐Acting Antiviral HCV Therapy: A Systematic Review, Meta‐Analyses, and Meta‐Regression

10.1016/j.jhep.2017.07.025 · 2017 · External reference

Direct‐Acting Antivirals After Successful Treatment of Early Hepatocellular Carcinoma Improve Survival in HCV‐Cirrhotic Patients

10.1016/j.jhep.2019.03.027 · 2019 · External reference

Impact of Direct‐Acting Antiviral Therapy for Hepatitis C‐Related Hepatocellular Carcinoma

10.1371/journal.pone.0233212 · 2020 · External reference

Impact of Direct Acting Antivirals on Survival in Patients With Chronic Hepatitis C and Hepatocellular Carcinoma

10.1038/s41598-019-53051-2 · 2019 · External reference

Hepatic Benefits of HCV Cure

10.1016/j.jhep.2020.08.006 · 2020 · External reference

Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV‐TARGET Analysis

10.1002/hep4.1412 · 2019 · External reference

Equal Treatment Efficacy of Direct‐Acting Antivirals in Patients With Chronic Hepatitis C and Hepatocellular Carcinoma? A Prospective Cohort Study

10.1136/bmjopen-2018-026703 · 2019 · External reference

Direct‐Acting Antiviral Therapy for Patients With Hepatitis C Virus‐Related Hepatocellular Carcinoma: A Nationwide Cohort Study

10.3350/cmh.2024.1015 · 2025 · External reference